Patient Support Services Contact Us

Investors

Overview

Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
05/09/19
REDWOOD CITY, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31 , 2019.  First Quarter 2019 Company Highlights •   UDENYCA®
05/02/19
Coherus Continues to Commercialize UDENYCA® Across All Segments REDWOOD CITY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade secret action brought by Amgen against Coherus that was pending
05/02/19
REDWOOD CITY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Bank of America Merrill Lynch Global
04/19/19
REDWOOD CITY, Calif. , April 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective April 18, 2019 , the compensation committee of the company’s board of directors granted six new employees, a Senior Vice President, and another Senior Vice President,

Copyright West LLC. Minimum 15 minutes delayed.